clinical trial · NCT03994705
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Multiple MyelomaDescartes-11FludarabineCyclophosphamide
brief summary
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
started
Aug 1, 2019
primary completion
May 27, 2021
completion
Jun 11, 2021
last updated
May 15, 2025
official title
Phase I Safety Study of Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol